Moderna vs the NIH & the Spikevax Patent Battle! – Ep. 38 [Podcast]
![Moderna vs the NIH & the Spikevax Patent Battle! – Ep. 38 [Podcast]](https://www.executiveip.com/wp-content/uploads/ep-38-redo-710x300.jpg "Moderna vs the NIH & the Spikevax Patent Battle! – Ep. 38 [Podcast]")
In this episode of Stuff You Should Know About IP, Thomas Colson and Raymond Guarnieri discuss a dispute regarding COVID-19 vaccine inventorship between the National Institute of Health (NIH) and Moderna. The NIH and the Biomedical Advanced Research and Development Authority (BARDA) invested in Moderna. Moderna has filed three patent applications, two of which relate directly to the mRNA-1273 sequence, and one of which is for a method of using the mRNA-1273 sequence. Moderna listed one or more inventors from the NIH on the patent application for the method of using the mRNA-1273 sequence, but did not list anyone from the NIH as an inventor on the other two patent applications.